Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Food Effect and DDI of Ascending Doses of the MEK Inhibitor Zapnometinib

NCT05555823 | Completed Phase 1

• 1 other identifier: ATR-002-102
• Study Type: interventional
• Target: 96
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to evaluate the safety and tolerability of ascending doses of the MEK-inhibitor zapnometinib (ATR-002) given as single doses (SAD Part) and as multiple doses for 7 days (MAD Part) in healthy subjects.

Conditions

Healthy

Outcome Measures

Primary Outcomes (1)

• Number of participants with TEAEs and SAEs, with abnormal ECG readings, abnormal vital signs, and abnormal laboratory parameters

  From 1st administration of study drug (SAD/MAD Day 1; DDI Day -1) up to 21 days after last dosing

Secondary Outcomes (23)

• SAD part: Cmax

  Day 1 to Day 7

• SAD part: tmax

  Day 1 to Day 7

• SAD part: t1/2

  Day 1 to Day 7

• SAD part: AUC0-t

  Day 1 to Day 7

• SAD part: AUC0-∞

  Day 1 to Day 7

Study Arms (2)

Experimental: ATR-002

EXPERIMENTAL

In the SAD part, study participants will receive IMP orally once (except for the first cohort), or twice (two single doses separated by an adequate washout period of at least 10 days for the FDI cohort, which will be conducted according to a two-period fixed-sequence design with all subjects receiving the treatment sequence 'fasted-fed'). In each of the periods of the MAD Part, study participants will receive the IMP for seven consecutive days. Dosing will start at 600 mg (SAD part) and 900 mg (MAD part) in the first cohort and follow the dose escalation schedule that is given in the study protocol.

Drug: ATR-002

Placebo Comparator: Placebo

PLACEBO COMPARATOR

In the SAD part, study participants will receive IMP orally once (except for the first cohort), or twice (two single doses separated by an adequate washout period of at least 10 days for the FDI cohort, which will be conducted according to a two-period fixed-sequence design with all subjects receiving the treatment sequence 'fasted-fed'). In each of the periods of the MAD Part, study participants will receive the IMP for seven consecutive days. In the DDI period with repaglinide two doses of ATR-002 will be given, and in the DDI period with celecoxib, four doses of ATR-002 will be given.

Drug: Placebo; Drug: Repaglinide; Drug: Celecoxib

Interventions

ATR-002 DRUG

300 mg tablets for oral intake

Also known as: Zapnometinib

Experimental: ATR-002

Placebo DRUG

matching tablets for oral intake

Placebo Comparator: Placebo

Repaglinide DRUG

0,5 mg tablets for oral intake

Also known as: Repaglinide-ratiopharm

Placebo Comparator: Placebo

Celecoxib DRUG

100 mg capsules for oral intake

Also known as: CELEBREX

Placebo Comparator: Placebo

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Capable of giving signed informed consent as described in Section 10.1.3, which includes compliance with the requirements, prohibitions and restrictions listed in the informed consent form (ICF) and in this protocol.
• Subject has been informed both verbally and in writing about the objectives of the clinical trial, the methods, the anticipated benefits and potential risks and the discomfort to which he/she may be exposed, and has given written consent to participation in the trial prior to trial start and any trial-related procedure.
• Study participant must be at least 18 years of age and not older than 55 years of age at the time of signing the ICF.
• Non-smokers or ex-smokers who had stopped smoking for at least 5 years prior to start of the clinical study.
• In good physical and mental health as determined on the basis of medical history and general physical examination performed at screening.
• Negative urine test for selected drugs of abuse at screening and upon check-in at the clinical site. Note: Subjects should not consume poppy-seeds within 72 h before screening and before each urine drug screening because this can falsify the results of the opiate urine drug test.
• Negative alcohol breath test at screening and upon check-in at the clinical site.
• Negative hepatitis panel (including hepatitis B surface antigen \[HBsAg\] and anti-hepatitis C virus \[HCV\] antibodies) and negative human immunodeficiency virus (HIV) antibody screens and negative SARS-CoV-2 PCR test.
• Body weight at least 70 kg for males and 60 kg for females and have a body mass index (BMI) ≥ 18.0 kg/m2 and \< 29.9 kg/m2.
• Male or female. Pregnancy and Contraception
• Female subjects must be of non-childbearing potential, as follows.
• A female study participant is eligible to participate if she is not pregnant or breastfeeding, and one of the following conditions applies:
• At least 1 year post-menopausal (amenorrhea \>12 months in the absence of an alternative medical cause and follicle-stimulating hormone \>30 mIU/mL in women not using hormonal contraception or hormonal replacement therapy) prior to screening;
• Surgically sterile (bilateral oophorectomy, hysterectomy, bilateral salpingectomy, or bilateral tubal ligation).
• To protect partners from possible exposure to study medication in semen, male subjects must use a condom during the study, even if they have had a vasectomy or their partner is not of childbearing potential, and they must not plan to father a child, or donate sperm, during the study, and for 4 months after their final dose of study medication. Note: medically acceptable methods of contraception that may be used by the partner include combined oral contraceptive, contraceptive vaginal ring, contraceptive injection, intrauterine device, and etonogestrel implant.

You may not qualify if:

• QTc interval of ECG above the upper limit of reference range at screening. The following commonly accepted reference range will be taken as a basis: Men: QTc ≤ 440 ms; Women: QTc ≤ 460 ms.
• Aspartate aminotransferase \[AST\], alanine aminotransferase \[ALT\], alkaline phosphatase \[AP\], glutamate dehydrogenase \[GLDH\], gamma glutamyl transpeptidase \[γ-GT\]) above the upper limit of the reference range.
• Presence of acute or chronic illness or history of chronic illness sufficient to invalidate the subject's participation in the study or make it unnecessarily hazardous.
• A condition that, in the opinion of the Investigator, could compromise the well-being of the subject or course of the study, or prevent the subject from meeting or performing any study requirements.
• Impaired endocrine, thyroid, hepatic, respiratory or renal function, diabetes mellitus, coronary heart disease, cancer, or history of any psychotic mental illness.
• Respiratory tract infection within 4 weeks before the screening visit.
• History of surgery or medical intervention, or planned surgery or medical intervention, that could interfere with the objectives of the study or the safety of the subject.
• Presence or history of severe adverse reaction to any drug, or sensitivity to components of the study medication.
• Loss of more than 400 mL blood, e.g., as a blood donor, or donation of blood products, during the 3 months before the study.
• Positive fecal blood test at screening.
• Active or latent parasitic infection, visit to a country with a high prevalence of parasitic infections within 3 months before receiving study medication.
• Use of any prescription or over-the-counter medicine, with the exception of acetaminophen (paracetamol), within 14 days (or 5 half-lives, whichever is longer) before the first dose of study medication as defined in Section 10.5.
• Treatment with any known enzyme inducing or inhibiting agents (e.g., St. John's Wort (Johanniskraut), barbiturates, phenothiazines, cimetidine, ketoconazole etc.) within 30 days before first administration of IMP or during the trial.
• Presence or history of drug or alcohol abuse, or intake of more than 21 units (14 units for women) of alcohol weekly.
• Receipt of a living vaccine within the 3 months, or mRNA or vector vaccine against COVID-19 within 4 weeks before dosing, or planned vaccination during the study.

Sponsors & Collaborators

• Atriva Therapeutics GmbH: lead

Study Sites (1)

Atriva study site

Neu-Ulm, Germany

Location

MeSH Terms

Interventions

2-(2-chloro-4-iodophenylamino)-N-3,4-difluorobenzoic acid; repaglinide; Celecoxib

Intervention Hierarchy (Ancestors)

Benzenesulfonamides; Sulfonamides; Amides; Organic Chemicals; Benzene Derivatives; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons; Sulfones; Sulfur Compounds; Pyrazoles; Azoles; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Masking Details: matching placebo tablets
• Purpose: OTHER
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: Randomized, double-blind, placebo-controlled, mono-centre; SAD, MAD, FDI, DDI part

Study Record Dates

• First Submitted: September 13, 2022
• First Posted: September 27, 2022
• Study Start: June 23, 2022
• Primary Completion: July 20, 2023
• Study Completion: July 20, 2023
• Last Updated: August 1, 2023

Record last verified: 2023-07

Locations

DE (1)